Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$45.18 – $94.28
40% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $539.7M | $701.0M | $968.1M | $1.06B | $1.20B | $1.80B | $2.37B | $2.94B |
| Cost of revenue | $440.4M | $563.3M | $748.5M | $793.8M | $872.6M | $1.36B | $1.82B | $2.35B |
| Gross profit | $99.3M | $137.7M | $219.5M | $266.5M | $331.8M | $440.4M | $545.8M | $593.5M |
| Gross margin | 18.4% | 19.6% | 22.7% | 25.1% | 27.5% | 24.5% | 23.0% | 20.2% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$28.7M | −$33.4M | −$866.0K | −$65.7M | −$69.2M | −$17.3M | −$39.0M | −$23.8M |
| EBITDA | −$18.0M | −$26.8M | $10.9M | −$42.4M | −$36.1M | $50.9M | $28.2M | $45.6M |
| Net income | −$33.6M | −$36.3M | −$16.8M | −$74.2M | −$77.6M | −$12.0M | −$45.5M | −$37.7M |
| Net margin | -6.2% | -5.2% | -1.7% | -7.0% | -6.4% | -0.7% | -1.9% | -1.3% |
| EPS (diluted) | -2.79 | -2.78 | -1.17 | -4.15 | -4.32 | -0.63 | -2.26 | -1.87 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3.4B | $-0.46 | $-0.47–$-0.45 | 1 |
| 2027 | $3.8B | $0.90 | $0.87–$0.92 | 1 |
| 2028 | $4.2B | $2.39 | $2.32–$2.45 | 1 |
| 2029 | $4.7B | $6.95 | $6.75–$7.12 | 1 |
Forward consensus · source: Financial Modeling Prep
SHOP APOTHEKE EUROPE NV
No one on the platform currently holds SHPPF.
No tracked institution reports a position in SHPPF as of their last filing.
No one on the platform has traded SHPPF yet.
| $2.1B |
| — |
| PHMMFPharma Mar, S.A. | $79.49 | +0.00% | $1.4B | — |
| PPTDFPeptiDream Inc. | $6.00 | +0.00% | $771M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.5× sales vs its 1.2× historical median P/S.
Fair value ≈ $157.03 · price $64.80 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.